I'm just going to take a quick minute before the next speech just to say hello to our online audience. Of course it's fantastic to have all of you here, but we also very much wanted to be able to have a broader audience from far-fung places, including people who are working on NCDs in different places of the world. So we had around 500 people sign up to watch online, and so far we've had some comments from Belarus, Kenya, Lebanon, Swaziland, Canada, and as far away as Greece, Sweden and Italy. So thanks to all of you. And if we haven't mentioned your country and you're watching, please send us a comment or a question so we can include you in the discussion. So for the next discussion, you know, in our first session we heard a little bit about how our traditional approach in humanitarian settings is not necessarily adapted for NCDs, but of course we have some good examples and evidence from another chronic conditions, which is HIV and TB. And so our next speaker, Helen, is going to discuss for us some of the lessons learned from HIV and TB programs. So Helen Bygrave is a primary care physician from the UK who describes herself as having been bitten by the HIV and MSF bug many years ago. So I'd describe her as a bit of a guru on HIV programs and MSF. So she's a good person to tell us about the lessons to learn. OK, good morning, everybody. I feel very honored to be invited to this event from the HIV department. So thanks for having me. But secretly, as Philippe said, I am a North London GP. So NCDs are kind of quite close to my heart as well. So I've been asked to come and talk about some of the strategies that we've been using over the last decade to help support the scale up of antiretroviral therapy and how some of these ideas and strategies might be transferable to the NCD context. So where are we now? Globally, 17 million people on ART. It's been hailed to be one of the greatest kind of public health responses and successes. And in terms of this concept of what can we learn and how can we leverage the experience of the HIV response in terms of NCDs? In contrast to the evidence, there's quite a lot of stuff that's been written about how we can link up and learn from each other. A nice piece here from the ICAP team. Another piece from Botswana, which is one of the most successful antiretroviral therapy programs and a meta-analysis looking at the elements, both at the multi-sectorial response that can be compared between HIV and NCDs down to programmatic strategies in the clinic. So quite a lot out there in the literature about how we can potentially learn from each other. But if I kind of come back to a little anecdote from one of my last field trips in terms of how this is really relating to what we're seeing on the ground, this is one of our community ART groups in Zimbabwe. They go once a year to the clinic for their clinical review and they take it in turns to pick up drugs for each other every three months. I'm going to talk a little bit more about that later. But when we're just chatting with them, I discover two of them have hypertension. They go every month to pick up their hypertension drugs. Quite often they're out of stock and they have to buy them out of pocket. Another one of them has diabetes and she has a four hour round trip once a month to collect her diabetes medication. So to quote one of my kind of clinical colleagues, I think there is a tension between how HIV services are being offered compared with NCD services. He describes when I'm doing HIV care, I'm driving my Rolls Royce. When I'm doing NCD care, I'm back in my old banger. So there is a tension around the systems that are being developed for HIV care versus noncommunicable disease. Three points I want to kind of frame my discussion around. The first one says the value of targets. Now we've had several targets over the over the years. Five by five, 15 million by 2015. And it's great to see now for NCDs. NCDs has been picked out in the sustainable development goals with I think it's to reduce by one third premature mortality due to NCDs. But do these targets speak to the people on the ground? Do they speak to the health care workers doing the job? In 2014, UNAIDS came with what are now the famous 1990 90 targets. A lot of us were quite skeptical of these and some of us are still skeptical of these. But I think what they've done is they talk to people at different levels. They talk to the national program managers, to district program managers and they talk to the clinicians and the patients on the ground. If I go to pretty much any clinic in the east and southern Africa, the staff know this. They are working towards the 1990 90 targets. It's clear. The other thing that these targets have done is in the first, I'd say, decade of the response, we very much have focused on putting people on to treatment. And I think quite rightly so. But I think what these targets have again have kind of pushed governments towards is to look at across the spectrum of the continuum of the HIV cascade, looking at testing, identification, so looking at that, how many people are actually being diagnosed. And what we know is that only about half people with HIV know their status. So it's a massive testing gap. But also looking at quality. It's no good just keeping putting people on treatment unless we know they're retained and unless we know they're responding to their treatment. So we're now having targets across that continuum of care from screening on treatment to quality outcomes. A lot has been said. It seems to be a bit of a bone of contention, the issue of guidelines. And I just want to say I have a huge amount of respect for the HIV department in WHO. They work tirelessly. And we have been really lucky to have over the years developed very evidence-based, pragmatic guidelines, initially very much focused on the when to start and the what to start. But what's come new in the first time in 2013 was a new chapter in the guidelines on the how to do it. So looking at the evidence, as Pablo has touched on, on kind of the service delivery guidance. How do we deliver services? And some of it is a question of how much evidence do we need for this? What do we need a randomized controlled trial for? What can we look at programmatic data? And what, quite frankly, is common sense. Do I need a randomized controlled trial to say it's okay to give my patient three months of drugs versus one month of drugs? Or can we sit together as a collective group of experts and make that recommendation? And I love the WHO recommendations that say strong recommendation, low quality of evidence. The other thing is we do need this research and we do need these recommendations because I'm sorry, if you want donors to put money into your programs, they want evidence. And they want to be shown that these interventions are cost effective. So if you want the Gates Foundation and Global Fund, et cetera, et cetera, to wake up to the burden and needs of NCDs, we do need to work together with the research community to generate the evidence to support these recommendations. The third point for me is we keep it very simple. Yeah, we recognize within stable resource constraints and setting, but even more if we're talking about delivering HIV care in Eastern DRC, in CHAD, in CAR, where we are providing HIV care and Ministers of Health are providing HIV care, we have to keep things simple. So the things we've really looked at simplifying over the decade or 15 years now really of scaling up is looking at the drug therapies we're using. So if we look back at the guidelines, in 2006, WHO gave Ministers of Health eight first line choices that they could choose to put on the shelf. It was completely confusing, yeah? In 2013, on review of the evidence I'm going to say in terms of looking at toxicity and looking at a regimen that we could use across populations, so adults, patients with TB, pregnant and breastfeeding women, we've come with one regimen that's clearly recommended to governments by this for everybody. So we have one adult regimen on the shelf. We've really looked a lot and lobbied drug companies a lot around fixed dose combinations. There's evidence and WHO has come in the 2016 guidelines with a clear recommendation on this, evidence that they support adherence, but not only do they support adherence, just from a very practical point of view, they simplify procurement, they simplify getting those drugs to primary healthcare settings. And if you want to scale up and decentralize, storage of this stuff is an issue. And by having fixed dose combinations, you almost halve your storage capacity, which is an important logistical point. Whether this is feasible in NCDs, I question, I think potentially that is an area for further research. There's a lot of conversation about polypill for prevention, but where are some potential gains in terms of treatment? I don't know. The other thing that we've looked at and demanded from the drug companies is heat stable formulations, yeah? I remember the days of the Lepinavir, Pantanavir capsules, had to go in the fridge. And unfortunately for pediatrics, we're still pushing the drug companies for improved formulations. But I think the example from MSF Switzerland, who worked together with some researchers in Switzerland, looking at the heat stability of insulin, has been really, really useful to say, it's okay to have insulin in a cool clay pot. And that's made a big difference for patients not having to come daily to get their injections. So what can we do in terms of evidence around current formulations that need cold shame? We've simplified the monitoring. And again, I think this is a very pragmatic response. We're very lucky now. We are moving towards viral load monitoring, but we've accepted by looking at the evidence that we're only going to do it once a year. We don't need to do this once every three months. We accepted with the regimen we're using, minimal toxicity monitoring. In all the projects I support, we don't do anything. We don't monitor carotidine for tonopovir. And we accept that small risk from a public health perspective. So again, if we're talking about using ACE inhibitors, what are we prepared to accept from a public health perspective? But we've also, and I say I've been involved in some interesting work over the last three years on viral load, worked very closely with the tech companies to say to them, this is not feasible. We're never going to scale up viral load if we rely on plasma. We cannot do it. The sample transport is too difficult. So in the space of three years, we've gone from one company that's approved to this. This is a dry blood spot for viral load. We've gone from one company being able to have a technology that we can do that to three companies having a technology that we can now do viral load on dry blood spots. In our project in Yambio in South Sudan, so quite unstable setting, intermittent periods of conflict, they have an HIV project which is a mobile clinic. They go out once a week to different assigned settings doing tests and treat, initiating people on antiretroviral therapy and they get a viral load. They do the DBS, they put it in an envelope, send it by DHL to a lab in South Africa and they get the results in two weeks. The other thing is the potential role of point of care and again, you have to know what you want and you have to go to the companies and tell them what you want. We're now looking at using a gene expert in settings such as CAR and Eastern DRC to do viral load and early infant diagnosis as well as TB diagnosis. And the third thing we've simplified, so we simplified the drugs, the monitoring, but also the way the models of care for delivering ART. The buzzword in the HIV, or buzz, I don't know, or buzzword, let me leave it at that in HIV at the minute, is differentiated care and differentiated ART delivery is part of that. The idea is that when we're designing a model of ART delivery, that we look first of all at these three elements. So what are the clinical needs of the patient? Do they just have HIV or do they also have HIV and diabetes? What sub-population do they fall into? Are they pregnant? Are they a child? Are they a part of a key population? And then what's the contextual factors? Is it stable? Is it a conflict setting? Is it urban-rural? Once we've defined those elements, we then use these building blocks to develop our model of service delivery. So the when, the where, the who, and the what. And these are the questions that have been addressed by WHO in these new service delivery chapter, the new service delivery chapter of the 2016 guidelines with very clear PICO questions addressing these building blocks of how we provide care. So for example, if we look at the when, there's a new recommendation to say it's okay. The outcomes are as good if you reduce the frequency of clinical and refill visits to three to six months new. WHO has made a recommendation that the outcomes are, in fact, often improved if we take treatment closer to the patient's home. So to decentralize primary care and in a new recommendation to further decentralize ART delivery to the community. Who's doing the job? And somebody raised this issue of human resources, which has been a massive challenge. There's no way we could have got where we are today without tar shifting. But there have been a number of studies because of this involves policy change within countries. And to change policy, it's very difficult to do that with a number of ministers of health if you don't have the evidence. So evidence to show that tar shifting to non-physicians has resulted in equivalent and in some cases again, better outcomes for patients. And a new recommendation that, to suggest that having the refills of drugs to stable patients can be done by lay carders. So just to give a couple more examples of these models of care that MSF has been working on over the last six, seven years. These are the community ART groups I mentioned at the start. They're being taken to scale at national level in Mozambique and Zimbabwe and pilot programs in a number of other countries. They're self-forming groups of people who live near each other between four and 12 in a group, stable adults on ART. And basically they take it in turns to collect drugs for each other. So they meet every three months, usually in one of their houses or another defined, another chosen community spot. And the group leader leads that group. They've had a bit of training and they complete a checklist of questions about health, so symptoms of TB, diarrhea, et cetera, yeah. And then every three months they nominate one person to go and collect the drugs for each other. And once a year they'll go together as a group for their clinical review and their viral load. Again, what we've worked on quite hard the last week is documenting the outcomes of these models, yeah, okay? And so what we're seeing now is uptake between 20 to 45% of our ART cohorts where this is being offered are going into the CAGs. It's resulting in decreased clinic visits. Retention appears to be good, particularly once you get looked past, they actually, we've got retention at 48 months which is much improved compared with conventional care. And the benefits of peer support in these groups have started income generating activities. And also we're working with these groups to mobilize for screening and testing, yeah. And I think what's interesting in Zimbabwe, the NCD patients have seen these groups meeting and doing their thing, yeah. And they've said, hang on a minute, what about us? So in our new project in Zimbabwe, what the team is about to do is to try from the start to set up these groups for both HIV and NCD care. And that's come from the patient's demand by seeing what's going on. The other thing we've seen in the countries where we've got these groups, or this model of care, is that in the event of a natural disaster, actually it's enabled us to continue care. In Mozambique, where we had periods of really severe flooding, we worked with the community health workers to take ART out to the group where they would meet the group leader in a defined place and they then distributed the drugs to the rest of the group. So again, it helped that contingency plan to continue care. And also we're starting to use these models in conflict settings. So we've got some examples just starting up in DRC and CAR. I'm sorry we don't have the outcome data from those settings yet, but I hope it will come. Because again, there is some anecdotal evidence that it's supporting continuity of care. Just a second example, adherence clubs. These are groups of 20 to 30 stable patients who are meeting these patients, these groups are meeting primarily in the facility. They're led by usually a lay worker and they receive, instead of queuing up one by one to see the nurse to get their drug, their drugs are pre-packed, there's a general group chat and discussion and then they just pick up the pre-packed drugs from the lay worker. Again, if we look at outcomes in the Western Cape in South Africa, there are now over 34,000 patients receiving their care in these clubs and 97% of club patients remained in care compared to a comparable group where 85% remained in care. Also there's benefit in terms of biological outcomes. The other important thing they did in the study in Western Cape is they've looked at cost showing that this model is more cost efficient, which the donors like. So building on the model that was developed in Kailitsha, what we've now done in Kibera in Kenya, and I'm sorry this wasn't picked up in your systematic review, I don't know, maybe it was. It was, alright. We've now tried to develop these medication adherence clubs. So again, 20 to 30 clients, they meet every three months, but we're grouping together patients with both HIV, diabetes and hypertension. Some of them obviously have comorbidities but some with individual diseases as well. They meet in the facility usually in the afternoon so they don't have to miss work or on a Saturday morning. And we've done some qualitative and we're starting more quantitative analysis of the outcomes, but from the qualitative work, it's really quite interesting because there was a lot of fear about doing this, bringing the HIV and the NCD patients together. But the initial experience is actually quite positive. There's a lot of sharing that goes on. There's a lot of cross-fertilization in terms of healthy lifestyle, the challenges of taking medication for life with the hypertension patients saying, oh, I've got a lot more pills to take than you. There's a lot of useful cross-fertilization. I think maybe we shouldn't be so afraid to look at how we can do this going forward in terms of an integrated approach. The other thing in Kibera is that it is a primary healthcare setting. All the services are integrated so a nurse can see somebody coming for acute diarrhea, one consultation, the next one is the HIV consultation and the next one is an HIV patient with diabetes. And that's been a real challenge and has taken a lot of investment in terms of training and human resources to enable the healthcare workers in that clinic to take that integrated approach to care. So I really feel NCDs and HIV are coming together. We're seeing more and more integrated screening strategies if we're seeing money available for door-to-door testing, outreach testing, more and more people are going out and doing both HIV screening, TB screening and taking the blood pressure. We've got clear guidance from WHO that all HIV positive patients should have their blood pressure taken and be screened for depression and more and more hopefully documented examples of these integrated chronic care clinics. But I think the issue of setting the right targets, having evidence-based guidelines but guidelines that then can be used in the clinic. A nurse in the clinic in Zimbabwe is not going to read the 600-page WHO guideline. Let's forget it, yeah? So we need simplified one-page field guides, whatever you want to call it, that clinicians can use on a daily basis to do the job. And it is possible, because I've done it for HIV, to put the 50-page chapter of PMTCT onto one page. It is possible. And I think if we want to make this a reality in these very challenging conflict, humanitarian settings, this is what we need to do and keep it simple. I just want to leave that slide up, because for me, the combination of those two things is actually what's made it work. Patient activism, yeah? And sustained donor funding. I'm really pleased somebody from the NCD Alliance is here. I'm gonna hear from them later on, yeah? But and I think one of the biggest lessons we could learn is why don't we get the diabetic patient activists, whoever they are, together with the HIV activists, because we've got 15 years of very good experience of how the HIV community has held healthcare workers and ministers of health accountable for delivering a quality service. So let's learn those grassroots lessons in terms of how we can work together to improve the quality of NCD care. Thank you. Thanks very much, Helen. Any questions of clarification for Helen? To Mum. Thank you. Helen, that's a very, very good point. Thank you very much about the activism and people coming up. And I just want to say that it has happened. The Diabetes Federation came and presented. I was on the Interagency Emergency Health Kit in 2008 and 2009, and they came and presented and requested that insulin, for example, sits on it, and it was rejected. It was rejected on basis that we didn't know it would survive without cold chain. We didn't know whether it would be accepted in country. But it's interesting, because this is a very good point. In HIV, at least as an outsider to HIV, it's easier because you have a single disease, incredibly high burden, and clear villains. And you don't have almost any of those in NCDs. You have a heterogeneous group of diseases, no villains, and no single solution. You could gather people around, give me a single dose, don't be greedy as a pharmaceutical company. We don't really have that, and it's very difficult to gather people around a vague cause that affects people variably, and you don't have a concentration, which is frustrating. I think this is one of your biggest problems, I'm going to be honest. I saw some dialogue, I can't remember whether it was the NCD Alliance website or the WHO website around this issue of what you're calling it. I mean, I think it is a problem to lump. How can you talk about diabetes and breast cancer in the same breath? I think it's a real challenge when the dialogue is NCDs. So yeah, I think that's an issue that needs to be fleshed out as we take the challenges of these diseases going forward. Any other clarification questions? Okay, so we need the, thanks, Helen.


In the previous video, we had learned some basic concepts of CSV and also wrote one CSV file. Now, it's time to see the real-time use case of CSV. Alright, ByteScout have provided pdf.co restful web API for document manipulation, data extraction or data conversion etc. Now, to show you how CSV works in real world, we will invoke one API of pdf.co in postman. pdf.co provides many APIs to manipulate pdf documents. From them, let's implement this document parser API which parses and gets data from pdf document using a predefined custom data extraction template. With this API method, you may extract data from fields, tables, values from invoices, any kind of statements, orders and other pdf or scan documents. So, this is the endpoint of the API. And then next, we need to set the registered API key in the request header. We will use postman to run this API. By the way, you can download this API request collection. Let me scroll down from this URL to import in postman. Now let's open the postman and let's try to understand some of the input parameters for this API in the postman itself. Alright, so I have already set the required parameter of this API. This is our API endpoint. Now let's understand the important parameter of this API one by one. First, let us start with the URL. This is the URL which points to the actual pdf file. So, here you can set the links from Google Drive, your Dropbox or from builtin pdf.co file storage. Now let's open this URL to see the pdf file from which we are going to extract the data. Okay, so this is the pdf file for which we will invoke that pdf.co API and this API will fetch this pdf field such as this invoice number, company name, account number, invoice date or say total amount, etc. Now let's see how this pdf.co API will fetch all this information. Okay, and then next we will set the template ID. So let me scroll down. So here we need to set the template ID. In our case it is one. So what exactly this template is? Okay, so here we have a sample template. This template is nothing but a yaml or json file which contains detection rules to extract specific data from the pdf document. Okay, and then next we will set the output format for this API. The output format indicates the default output format of the API response. In our case we will set it to CSV and then next parameter is generate CSV header. In our case we want to generate the CSV header. So we will set it to true over here and then last but not the least setting API key in the header part. I have already set my registered API key in this request header. So now it's time to invoke this API. So for that, let me click on this send button to get our API output. All right, so here we go. You can see here the API station formatted response. Our actual data is resided in this body object which contain pdf extracted data in CSV format. So now let me copy this content and paste in one CSV file. All right, so let me paste our API response in this file. Let me paste and now let's save this file. Now let me open the file location. Now let's open this file in Microsoft Excel and compare our extracted fields side by side with the actual pdf file. All right, so as you can see here that company name is extracted from this field and same way invoice ID is extracted from this field and this is the invoice date which you can see over here and same way you can see the bank account number which is extracted from here and this is the total invoice amount which is extracted from this field. So this is how you can use this API as per your requirement. Now the next video is going to be very interesting for you. In the next video, we will see how and from where you can change the default separator for the CSV file in windows settings. So to know that, stay tuned with us.


Bemidji residents have raised questions over the newly proposed city liquor store. Josh Peterson takes a look at the variances that were granted for the project. For years, the city of Bemidji has been looking at replacing its current liquor store on the city's north side. But over the past few months, questions have been raised over the variances issued for the new store. We did have some push back for the most part. The joint planning board followed the way the bylaws are put in place. The variances that were issued by the joint planning board dealt with the proposed building setback from the roadway and the number of parking spaces the new facility will have. The city of Bemidji says they followed proper protocol. We don't feel that we received any sort of preferential treatment at all. We actually conversely followed the same process that everybody else has gone through. Because of how narrow this stretch of property is, here along Paul Bunyan Drive, the city of Bemidji has requested multiple variances so that they can build the new liquor store on these two parts of the land. Similar variances have also been issued to multiple other businesses along Paul Bunyan Drive. With many businesses redeveloping their property along the business corridor, the lay of the land is so unique that many variances have been issued. When the city does have a lot of variances they issue and we have issued variances along the stretch, it's common for a city to take a look at its code and maybe retool that code a bit. With so many variances being issued, the joint planning board will take a closer look at the ordinances and possibly make revisions in the future. We're going to review these areas. That's the thing is you should have a lot of variances over time that you're awarding. And if you are, then that's something that maybe you should be looking at. In Bemidji, Josh Peterson, Lakeland News. The new city liquor store is expected to break ground in May. If you enjoyed this segment of Lakeland News, please consider making a tax deductible contribution to Lakeland PBS.


Hi everyone, I'm Joe for jaspyscasefrakes.com coming at you with an autographed baseball 2022 fanatics under wraps one autographed baseball random team break number one The last fill or the only filler actually we had to do to unlock that hip parade dual case break baseball break That's gonna come up in the next video top nine. We'll we'll get spots, but first The break itself. This could be interesting big. Thanks everybody here for making it happen There are the teams right here. Let's roll it and randomize it three and a three six the hard way one two three four five and six Now we're going by our no checklist rules. I think you saw that in the description So if it's an active player to go to the team they're currently on and if it's a inactive or retire player I'll go to the team he played for the longest three and a three six times for the teams unless There's some like obvious like inscription if it says like I Don't know if it says like Sayang 1991 or whatever Then it'll go to that that year's team Jose Rio maybe for the Cincinnati Reds. All right. So where am I after six? Right white socks down to Rangers and no trade windows here. We just want to kind of get this done quickly Here's the first half of the list right here second half of this right there Let's alphabetize by team And good luck Actually, I don't think I even need to print this soft. I'm gonna tag the tag the box. All right, there it is We also have a nine box break of this they come in 18 box cases. I have a nine box break of this a random player break Should be pretty fun It's just out in the open, huh? I see an HOF inscription. So that must be for a team that he's played for the longest Do they put the player name on here? Oh, I see it All right, um Let's play who am I let's play America's favorite game. Who am I? We haven't done this in a while This gets the people going and show off your your trivia skills Who am I? I was born in 1918 passed away in 2010 at age 92 a right-hander a pitcher Played for one team my entire career interrupted for a few years by World War two an eight-time all-star a world series champion in 1948 a pitching triple crown in 1940 a six-time AL wins leader AL era leader and A seven-time MLB strikeout leader through three no hitters in my career one in 1940 46 and 51 My numbers retired the team is retired or I'm in that team's Hall of Fame and Got into first ballot Hall of Famer in the early 60s with 93 point seven five percent of the vote served in the Navy on the USS Alabama Chief Petty Officer in the On the ocean in the Atlantic and the Pacific theaters Oh, let me give you some stats win-loss record 266 wins 162 losses lifetime three two five era and a and 2581 strikeouts I'll give you he's got three nicknames a corner wikipedia Three nicknames one of which will give it away two of them might be a little bit more difficult first nickname Nickname the heater from van meter He was born in van meter, Iowa other it nickname Rapid Rob Rapid Robert. I'll give you his most common nickname up there. Diego's got it the most common nickname Bullet Bob nice Bob feller Hall of Fame inscription as well Got the fanatics authentic logo. You got the MLB Authentication logo as well. So all official It's even says that on the card down there makes even more official So who's got the tribe the tribe of guardians now? Indians back in the day and that is Martin Doring last spot mojo Got randomized Cleveland Cleveland. This is for you All right. Now, let's see who's gonna win spots in that hit parade break top nine We'll get in top nine after Four and a five five and a four nine times top nine after nine one. Good luck two three four five six seven eight and Fingers crossed ninth and final time after nine So it's only the top nine so from ten on down Apologies to Michael for now You might be up in the up top there, but from 10 through 30. Thank you everyone for giving this a shot Thanks for taking the risk Only the top nine can be happy though Martin is happy. So is Martin again and again and again. Is he gonna sweep this? No, Michael. See there you go. You got it Michael. Oh Most wow, I don't think I've ever seen that before Martin with eight. I mean he did get a lot of spots, but eight of the nine spots Very nice Michael Lossia you snuck in there as well after nine times We'll see in the next video for the break. Jasper's case breaks.com


Hello and welcome back to the learning analytics course. This is the last learning dialogue in this course. I thank everyone who registered for this course and I hope you enjoyed this course. In this course we saw that what is LA, what is solar community, what is EDM community, how this LA has come up from these two communities. Also we talked about all the types of analytics, learning analytics like diagnostics, descriptive just what is that. And we discussed with detail about what are data to be collected in MOOC, what are data to be collected in teleenvironment and how to collect data in the classroom environment. We did not see much detail about how to visualize this data, the visualization like once based on what is your purpose. If you are collecting data from class of 50 or 60, you cannot plot all the 60 points in the data. Instead you might need to compute the mean or average or the performance in a different buckets like a student's performance from 20 to 30, 30 to 40 something like that. So, it depends on your requirement of the research question. And we talked about ethics and privacy. It is very important before collecting any data. We need to inform the users that we are collecting data and the user also have some rights that they can participate in the course and they can say they do not, they do not want to participate in the data collection process. During the interaction, they decide not to do anything. And we talked about predictive analytics like linear regression. I talked about only one predictive analytics model, linear regression just to say how this predictive analytics model look like. If you are interested, you have to learn more about that. You have to go and learn about different predictive models exist in the machine learning tools like VECA or RapidMiner. And also we discussed the demonstration of the VECA tool. I hope you enjoyed taking this course and you will enjoy doing this project, small mini project for this course. And you will able to take the exams very well. The aim of this course, when I started this course, the aim of this course is to just to introduce what is learning analytics, not to teach a very deep concept in learning analytics or not to teach a multimodal learning analytics, something like that. This aim is to introduce the terms we use in learning analytics and how can you apply the data you collect in the learning analytics and you can interact with someone who is working on learning analytics in their language. That is the goal of this course. I hope I achieved that. So, what is NEST? Please read books, more books. As I mentioned in the first lecture, there is no standard book, but go and read the research papers in Helike conference, an EDM conference. When you read a papers now, you might able to understand the research and you see what data collected, what is the tool they used, what is algorithm applied, read those things and you get more interested in it. And please learn about non-linear classifiers. As I mentioned, linear regression has a linear assumption between these two data. It may not be true always. There are a lot of very good classifiers, non-linear classifiers, ML based classifiers, probability based classifiers. Please learn them. And we saw linear regression because it is very easy to start with. And collect data, please follow the ethics principle and privacy of the learners. Collect data in whatever environment you are working on, classroom environment or the tally or the MOOC or any other programming lab, please collect data then do the analysis. When you collect data, you need to come up with the list of variables, independent variables that will impact the dependent variable. The dependent variable in our example is performance, but in a course project is dependent variables whether the student will drop out or not. So, the dependent variable is based on your research question. Please try different tools. We saw VECA, but try different tools like rapid miner is very good tool, orange. These tools actually gives a free license for the academic use. If you have an email id which ends with academic.in, ac.in, you will get this tool for free. We plan to offer a next course, a tool weeks course with the more deep concepts and rigorous on learning antics called learning antics tools. We will discuss more about the tools we use, not about the data collection, instead we call talk about what tools we will use and different tools not just VECA for the diagnostic antics is there any tools, is there patent mining, is there a tool called rapid manner it can be used, what are the other algorithms, we will discuss that in detail in the tool weeks course. Thank you for taking the course again. Thank you.


You look good enough now.  It's I'm Corbyn. I'm sorry Personally YouTube channel. Yes there good things happen over there Today we're acted to two little short clips. Tell me about it, Corbyn. This is actually I'm gonna talk about John talking about Say his name. Oh, yes superstar. Yeah, we've seen it in a few videos that Michael Jackson Choran GV. Yes Because I believe it was his birthday or something and so somebody wanted to hear I'm gonna talk about John talk about him So there's just I think two like minute little clips Okay, I'm a top who we know very well and this other gentleman who we only know from a few videos Yes, um, so these are just so these are both big B clips both just short big clips talking about him Got it. Um, so And hey And if I'm not mistaken everybody in the Bachchan household is home and healthy. I believe so. Yeah, that's great Everybody's home. So that's fantastic. That's my happy to hear that Here we go The film industry ladies and gentlemen and all your wonderful fans of children It's much larger than any other And I think I Don't know but that's that's high praise. I've actually seen big B Do that with lots of huge stars from different like I think he's done it with mohanum as well from on the album and then I'm sure I can rush the content was in that short that he did during quarantine And so I'm sure they all know each other because big B is huge as we know over and he's like call it Indian cinema Right, don't yeah, even in the very opening of the book on Bollywood cinema He writes the introduction to it and straight up in the Bollywood books as I don't like that term It's Indian cinema and he himself has done more than just Hindi language for his films And I also was recognizing something with this Have you noticed gotten requests and we can't do this for everybody? But there's there's often been many requests for someone to say, please take my name. Please say my name Did you notice when he spoke his name the response? And I don't think it was just because they want to cheer me to cheer of Angie Yeah, when he said his name in the same way and correct me if I'm wrong But I think the impression I get is that Isn't just for the recognition that there's a level of blessing that happens if you Actually speak the person's name in the same way for example that what they would do is touch an elder's feet to receive blessing That it's and on birthdays you get birthday wishes of don't just wish me a happy birthday, but please bless me I Think there's something very very important about somebody you admire Speaking your name and because I noticed it was they weren't just cheering. I could hear this sound of like yes Big B said his name and So correct me if I'm wrong, but I think that's that's a reason behind the speak the name and clearly You know, do you think Big B? So the most respected and known like I mean loved actor in India That's the impression we get I mean I know Shah Rukh Khan is huge, but I feel like yeah, like not he's not I don't think he's necessarily what he's quote-unquote Favorite per se like fan favorite, but as far as I I don't think you have a higher level of Cinema royalty than I'm a tabak John, but you know everybody would probably tell us we're wrong But but but outside of Hindi I would assume it seems as if the biggest name in in Indian cinema that that garners the greatest respect is on the tabak John You could be wrong And this the second clip is just another short one. Okay, I Have been in my office films and books for a very long time and then I think if I if I'm not mistaken, sir We were shooting together in Ooty I was shooting for hum hum. That's right. And you were doing a sequence a song sequence And we were pretty close to the same location, you know And so I suddenly found out and I went across and he was doing a song sequence And really what amazed me was that We sat we chatted and then the chat with The very complicated dance movement He just did it in one take That is over something that I would have taken a couple of years to be Before actually We know that we know that less your heart be honest But that's how we met and then we we we keep reading it on and off And we keep talking to each other I don't know why the audio audio that weird thing. Yeah, I do With cheer Ranji from the little we've seen of him and his couple of songs And I think most of them are from patreon. So sorry guys Um Is much better dancer than big b. Oh, yeah, but we'd love to watch a big b dance We always root for big b when he dances, but he we understand it's an effort He's not a natural dancer by no by any stretch. So that's great that he said it's always really cool to see the And obviously like I said, the big b is a big Advocate for all of indian cinema. Yeah, um, not just bollywood and and every single region from what I found is I'm not saying everybody in there is partial, but they're you're very they're very partial to their own industries Yes And what we're hoping is that that can be fine, but also Love and explore other industries. Yeah, especially if it's good art the fandom is almost as diehard and Unaccepting as sports franchises here in the u.s. Yeah, it's probably worse. So Yeah, it's like uh-uh because if my region is better than your region And if I put like two two days with south indian reactions All the hindi people are like there's way too much Might as well call this our our south indian reactions And then if there's two like two days of just hindi reactions Oh, might as well just go the all these guys only like bollywood. Yeah Yeah I try to get to everybody Uh, but you know can't please them all can't please them all but that's what we're hoping for is that Even if you like one the most Still support good art everywhere. Yeah, that's what we want. Yeah, it is It's it's sports is it's a competition art is a collaborative effort Yeah And you should be rooting for each region to be as good as it could possibly be Yeah, so anyways, that was cool. Let us know more uh cheer avenge cheer Cheer avenge uh stuff that we should react to down DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN DIN D


Hey guys, it's Liana and I'm here today with my June TBR. So, TBR, June. Great, plenty to explain that. Plenty to explain as we go. I have a lot of like collaborative projects on the docket in June. Oh balls! I forgot to look. Well, let's go ahead and go with the one that I forgot first since I just grabbed it and that is Ariadne by Jennifer St. As I have stated multiple times, my goal or my method, my project, is in order to keep up with my Book of the Month book books is to read each book of the month and the subsequent month. So this was my May Book of the Month, therefore it is on my TBR in June. You've seen the UK cover? It's way better. This is okay though. I really like the colors of this cover. This is my expert assessment. That's what you're coming here for, for my assessment on colors. I really like the colors, I mean it's orange and this nice teally blue. Not just my couch kind of, but the design of it, not loving it. The design of the UK one? Beautiful. Anyway, this is a retelling of a Greek thing, I think. I see the word minotaur, Prince of Athens, blah blah blah. Yeah, it's some Greek thing. I mean basically what I'm getting out of this is it's like following in the footsteps of like Madeline Miller doing like a retelling of some Greek stuff. But in like a narrative feminist, lit-ficky way. It's not terribly long and it is my Book of the Month from May. So that's that. Next two I'm going to do together because they are part of the same project. For a long time now I've been wanting to and then just it hasn't been a priority because there isn't like anything going on that I would need to like do that for. But I've been wanting to read the Hogarth. Why did I say that's so weird? The Hogarth Shakespeare books, which are these retellings of Shakespeare plays that a lot of famous authors have been kind of called upon to write. I think this is the first one that I heard of and I think it might be the first one that they did. But I haven't read any of them yet so it doesn't really matter. I've been collecting them and not reading them. But in any event, the Shakespeare play The Tempest, which I intend to read in June as well because I want to have read the play very recently before picking up the book. So The Tempest by Shakespeare. I'll be reading it because I will then be reading Hangseed by Margaret Atwood, which is the retelling of The Tempest. And the reason this has become like a thing now, even though I've wanted this to be a thing for forever, I've been wanting to back-to-back read the play and the book, the play and the book for all of the Hogarth Shakespeare retellings. I'm doing it now because I recently was talking on Instagram about how much I've been loving Broadway HD, which is the subscription service where you can view a lot of plays, tapings of plays. And a lot of them are Shakespeare, like Royal Shakespeare Company productions. And me, both deprived of actual theater during the pandemic and just generally being a Shakespeare nut, have been living for it. And I was talking about this on Instagram. Any longtime friend of mine on Instagram messaged me and I did not know this. And I was like, how did I not know this? I knew that she had gotten her doctorate, did not know that her thesis was on Shakespeare. I was like, why did I know that? She was like, because it's kind of like a big, it's a great conversation ender to be like, well, actually my doctorate in Shakespeare. And I was like, I'm so excited to have somebody that out nerds me on Shakespeare that won't think that I know too much about Shakespeare. You know more than me, which is super cool. Anyway, she is going to be reading these with me and I'm going to have her on my channel so we can talk about it. So at the end of the month, we'll both have read The Tempest and Hagseed and she'll be coming on my channel so we can chat about it and like nerd out about Shakespeare. And I'm so pumped for this because I never have anyone to nerd out about Shakespeare with. So I'm so, so pumped for this. I don't know if anyone else is excited about this. I'm so excited about this. So anyway, look out for that. That'll be at the end of the month. And if you would like to read The Tempest and Hagseed and come chat with us, please do so. If you'd like to check out Broadway HC, Royal Shakespeare Company does have a production of The Tempest that you bet I will be watching after I read both of these. So pumped for this. So pumped. Next is a book that I have pre-ordered and it will be arriving before the start of June, but I am filming this ahead of time so I don't have it yet, but I have a placeholder here so that I don't forget. And that is The Black Tongue Thief by Goddammit, who's it by? By Christopher Buhlman. Yeah, this is obviously not it. The Black Tongue Thief is grimdor fantasy about student debt. It's how I keep telling everybody about it. I haven't read it yet, so maybe I'm wrong, but based on the synopsis, that's what it sounds like to me. I'm very excited about it. That's all I have to say about that. Oh, and I guess I've heard good things about it. I should say that too. So I have reason to believe that it is as good as it sounds. Next up for Project Abercrombie is The Red Country by Joe Abercrombie. Do I need to tell you again? Do I? Why I'm reading this? You know. I don't need to tell you. So yeah, Red Country is next, and you know why. Next, next is another book I don't have a physical copy of, and that is The Blades and Bottleshopers Book Club Pick for June. This is Amanda's pick, and it is, I haven't even said what it is yet.  It is by Rocha Oroca. I don't know how to pronounce it. It is a mercenary librarians novel. I was quite excited about this until someone told me that it is a paranormal romance. Is that what it's called? I don't know. I haven't read it yet. Having stabby librarians, that sounds great. Paranormal romance, not my speed. So we'll see how I do with this. You'll see how I do with this on Amanda's channel at the end of the month, when Blades and Bottleshopers gathers to discuss it. Next I have this massive tome, which is Dark Age by Pierce Brown. I have already read this. I don't know if I'll actually read all of this again, but if you don't know, my good nemesis on over at the Library of Alexandria, Alan, has been doing a Red Rising read-along with live shows to accompany this at the end of each month. And he invited me to discuss Dark Age with him on his channel, as well as Alex Nieves. So we'll be over there chatting Dark Age. I want to refresh myself on Dark Age before said chat. Again, this is a commitment. It is an excellent book, but it has earned its name.   Every time I've talked about Dark Age, I've been like, that book may amount. Talk about changing the paradigm. Did not know that like any of this was an option in this universe. I spent half of this book just going, what? Since when? So yeah, I'm at the very least gonna kind of skim and like read like certain parts of it that I remember being like extra bananas to refresh myself on how bananas they were. Also, because I have the sub-presedition and like I want to properly kind of look through it and all of the illustrations. And I think it would be fun to look at the illustrations as I reread it, you know, like have the scene freshen my brain and see the illustrations. So yeah, super duper pumped for this. Yeah, so join us on Ellen's channel at the end of Jim. Next is another book that I will, well, I don't know if Alex is going to reread Dark Age. He'll probably skim it, like me at least. But he and I will be reading Empire of Silence together by Christopher. Oh God. By Christopher. I've had this book on my shelf for a while and I keep wanting to read it like I want to read all the books that I own and not getting around to it. And then Alex recently hauled it and I was like, I've been wanting to read that. And he was like, great, let's read it. And I was like, great, let's read it. So Alex and I are gonna be buddy reading Empire of Silence. We're gonna be chatting about it mid month on my channel because there's something freaking live shows at the end of the month. So I can't do them all at the end of the month. I will already be talking Blades and Bodice Rippers, The Tempest and Dark Age at the end of the month. So he and I are aiming for mid month for a chat on my channel to talk about Empire of Silence, which I've heard only exceptional things about. And this is the start of a series for sure, I think, as a trilogy. Yeah, I'm excited. I'm gonna want to read this. We're gonna do it. We're doing the thing. It's got a lot of sci-fi, not a lot of sci-fi. That's just too sci-fi. That's more than usual. So, pout for this. And last, yes? Possibly? Yes. Last but not least is Dreams of the Dying by Nicholas Leesow. This is the patron buddy read for June. So me and my patrons will be buddy reading Dreams of the Dying, which I've heard again exceptional things about.  This is like the art on the cover. It's that buttery kind of cover that, oh, I just love it. And then the Naked Book has that same cover on it. I mean, this cost pretty penny.  Aesthetically worth it. Hopefully the book lives up. Again, I've heard great things about it. I think there are illustrations in the book. Well, there's a whatever that thing is that looks adorable. Don't wanna look too much in case any of that is spoilery. Anyway, I've heard amazing things about this and I'm excited to read it with my patrons. And I believe they're excited about it too, since this is what they voted on. So it would be really masochistic to vote on a book that you don't wanna read. That's what I will be reading in June. Let me know in the comments down below what you'll be reading in June, if you've read any of the books that I've read, if you plan to read the books that I've read, if you'll be joining me on reading any of these books so that you can join in any of the various live discussions that will be occurring in June. It's gonna be a pop in a month. Love you to all of the things. I post videos on Saturdays, other random times as well, but definitely Saturdays. So like and subscribe, draw my Patreon if you feel so inclined, and I'll see you when I see.


The respiratory hospital did receive a complaint from the family members of a patient who was admitted at the facility. The complaint expressed many concerns which carried the clinical care the patient received while admitted, the form of discharge from the facility and a request for free clinical review and follow-up care post discharge. The matter was thoroughly investigated. We acknowledge that unfortunately the wrong information was inadvertently communicated to the patient's family. This situation has caused the hospital to strengthen its processes for reporting information to patient's families. We will continue to work with the patient and the family to bring an amicable resolution to this unfortunate situation. We cannot discuss any details with the public as we are bonded by doctor patient confidentiality. We would like the public to know that as the pandemic continues to affect St. Lucia as an island and of course our healthcare workers at the hospital, we will still continue to provide the best possible care and save lives.


Warning, the video you are about to see contains harsh language and may not be suitable for all audiences, viewer discretion is strongly advised. Hey guys, Shaber1000 here. Now this is just kind of a little rant I guess.  I'm gonna show you a clip. And it's unfucking believable. Excuse my French, but this really pisses me off. I don't know if it's the parent's fault or the kid's fault, but I'll give you a little insight. I got outside yesterday, opened up the garage door, and I got outside to work on a little boat motor.  Cars going past.     Cars are going past with kids in the cars. You'll see it. I'm gonna show you the clip. And I just can't get over what is wrong with society.   You ain't no gangster.     Is it the parents? But even at that age, they know right from wrong. But this just pisses me off. So take a look at the clip and I'll explain you what's going on and kind of what's being said. The clip has no sound because I don't have a microphone on our security cameras, but I'll narrate it for you. And then I'll come back with you with my final thoughts. Okay, guys, right over here, you'll see this this kid. There he is. The guy's telling you about about 1516, maybe in 17. But I think you've seen him looking over, I think because that's about the time I opened up the garage door, the big garage door. They make a lot of noise. So he had to hear me coming out. Doesn't bother him a bit. As you can see, he's he's across the street, but he's like right behind the mailbox. Now, you know, I didn't pay any attention, but then he walks over this way. Now I hear him and I look. So I'm thinking nothing of it. There's a kid there and then all what's I hear him pissing. Now there goes a van right there. Many van with kids in the car. So I'm telling him, hey, this ain't your personal urinal. What do you think you're doing?  I've got a video camera and I watch what he does. He flips me off right there. Then he flips me off again. And he's he's going, you know what?   Well, so I'll bust a cap in there as to or whatever.    Okay, guys, what is going on? What is going on?   Okay, guys, you see what I mean?  I opened the big garage door. Okay. That makes some noise. I mean, even looks around. If you watch him, he looks around.  You know, you don't do that. You don't do that.  Just stand there and piss like nobody's business, man.        I don't want the fucks around with society, but it needs to stop.  You know why? Because we're not allowed to punish our kids anymore. We're not allowed to discipline them. Put them in the corner. That don't always work.  You know, why take that away and then complain about what's wrong with society? What's wrong with society? What's wrong with services?  So anyway, that's my rant. So sorry for the harsh language, but hey, you know, it is what it is. You know, so anyway, guys, Shaber 1000 met the man legend. Thanks for watching. I'm gone for now. Take care, guys.